<DOC>
	<DOCNO>NCT02682823</DOCNO>
	<brief_summary>This study design evaluate RLHFs concern administration tocilizumab autoinjector AI-1000 G2 adult rheumatoid arthritis ( RA ) receive subcutaneous ( SC ) tocilizumab use commercially available prefilled syringe needle safety device ( PFS-NSD ) . The study enroll participant RA , subset assign perform self-injection AI-1000 G2 . Enrolled caregiver ( CGs ) health care professional ( HCPs ) administer AI-1000 G2 injection remain study participant . The study enroll approximately 45 participant RA across three cohort . Group 2 also include 15 paired CGs administer injection , Group 3 include 15 paired HCPs administer injection . With expect drop-out rate 20 % , target enrollment ( achieve final sample/ratio 45:15:15 ) 95 individual overall .</brief_summary>
	<brief_title>Tocilizumab Real-Life Human Factors ( RLHFs ) Validation Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Participants RA &gt; /=6 month receive 162 mg tocilizumab PFSNSD least 8 week suitable continued treatment currently prescribe dose CGs professionally qualify HCPs able willing administer injection RA : Functional status class IV RA : Neuropathies condition might interfere pain evaluation RA : Pregnant breastfeed RA : Low neutrophil platelet count last laboratory assessment RA : Elevated liver enzymes last laboratory assessment Current participation another interventional clinical trial Criteria might give participant/CG/HCP advantage injection task employment pharmaceutical industry , etc .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>